NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
Clinical Trials
31 trialsNCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT07450599 2026-04-14
CHINANEO
Bayer
Phase 2 Not yet recruiting
NCT05818683 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06190899 2026-04-13
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT07190300 2026-04-08
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT06120491 2026-04-03
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT05059236 2026-04-02
ARASEC
Bayer
Phase 2 Active not recruiting
NCT07103018 2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT05348876 2026-03-19
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Bayer
Phase 4 Recruiting
NCT05794906 2026-03-17
ARASTEP
Bayer
Phase 3 Active not recruiting
NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT05938270 2026-02-24
ASCERTAIN
AstraZeneca
Phase 1 Recruiting
NCT05997615 2026-02-24
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT07140900 2026-02-13
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen
Phase 1 Recruiting
NCT07244341 2026-02-04
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting
NCT05519449 2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1 Recruiting
NCT05367440 2025-12-08
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT02799602 2025-12-04
ARASENS
Bayer
Phase 3 Completed
NCT05413421 2025-08-11
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT02200614 2022-06-28
ARAMIS
Bayer
Phase 3 Completed
NCT01784757 2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1 Completed
NCT03237416 2018-11-06
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Bayer
Phase 1 Completed
NCT01317641 2017-03-29
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Orion Corporation, Orion Pharma
Phase 1/2 Completed
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed
NCT02671097 2016-09-08
Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate
Bayer
Phase 1 Completed